■ The major risk factors for
degeneration, or AMD, are:
being over the age of 50;
smoking; being white; and
having a family history of AMD.
DID YOU KNOW? ■ My Retina Tracker is FFB’s free,
secure and confidential registry for
people with retinal diseases. Those
who register can keep track of
disease progression and, by granting
permission, allow researchers to
use the disease data collected to
develop treatments and recruit
participants for clinical trials. For
more information, or to register, go
Press on Stargardt Disease
A Stem-Cell-Derived Therapy
to Save Vision
The biotechnology Ocata Therapeutics
is conducting a clinical trial of transplanted RPE derived from stem cells.
By replacing lost RPE with healthy RPE,
clinical investigators hope to preserve
photoreceptors and thereby save vision.
The Foundation funded several years of
earlier, lab-based studies that made the
Ocata trial possible.
ProgSTAR Natural History Study
The Foundation is investing $5 million in
a 250-patient, international natural history
study of Stargardt disease. A major goal
of the study is to monitor disease progress
to identify the best measure for quickly
and accurately evaluating a treatment’s
effectiveness in a clinical trial. Armed with
a powerful outcome measure, companies
and researchers around the world will be
better motivated and positioned to conduct human studies of emerging Stargardt
For more information on these research
efforts, visit www.FightBlindness.org or
These images (l. to r., starting at top) show a blind spot, in the
center of a Stargardt patient’s retina, growing over five years.
Images courtesy of ProgSTAR- 1 Study.